US Stock MarketDetailed Quotes
CGTX Cognition Therapeutics
- 0.428
- -0.012-2.75%
Close Nov 22 16:00 ET
- 0.429
- +0.001+0.30%
Post 20:01 ET
17.77MMarket Cap-445P/E (TTM)
0.446High0.414Low263.94KVolume0.437Open0.440Pre Close112.92KTurnover0.75%Turnover RatioLossP/E (Static)41.55MShares2.95052wk High1.23P/B15.12MFloat Cap0.34052wk Low--Dividend TTM35.35MShs Float13.800Historical High--Div YieldTTM7.19%Amplitude0.340Historical Low0.427Avg Price1Lot Size
Cognition Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -64.65%-6.85M | -62.26%-6M | -167.80%-7.24M | 13.57%-16.02M | 46.43%-5.46M | -103,925.00%-4.16M | 31.01%-3.7M | 9.47%-2.71M | -410.41%-18.53M | -10,183.17%-10.18M |
| Net income from continuing operations | -47.24%-9.94M | -48.98%-7.04M | -48.27%-9.15M | -20.52%-25.79M | -57.10%-8.14M | -1.87%-6.75M | 17.84%-4.73M | -60.81%-6.17M | -82.63%-21.4M | 29.39%-5.18M |
| Operating gains losses | --0 | --0 | --195K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 7.69%70K | 9.84%67K | -3.33%58K | 7.23%252K | 10.00%66K | 8.33%65K | 3.39%61K | 7.14%60K | 152.69%235K | 160.87%60K |
| Other non cash items | ---- | ---- | ---- | --318K | --0 | --0 | --0 | --318K | ---- | ---- |
| Change In working capital | 46.01%2.12M | -203.57%-170K | -74.61%483K | 613.89%4.85M | 125.96%1.55M | -74.90%1.45M | 89.93%-56K | 1,018.84%1.9M | -133.18%-943K | -366.49%-5.96M |
| -Change in receivables | -135.76%-270K | -185.46%-2.24M | -79.64%420K | 270.06%2.39M | 131.21%357K | -38.82%755K | -56.49%-784K | 307.34%2.06M | -26.21%-1.41M | -4.47%-1.14M |
| -Change in prepaid assets | 122.86%468K | -37.14%518K | 909.72%583K | 242.24%1.85M | 408.57%890K | 121.28%210K | 39.19%824K | 93.35%-72K | -6,300.00%-1.3M | 348.72%175K |
| -Change in payables and accrued expense | 242.56%2.3M | 39.11%1.73M | -402.67%-377K | 425.77%2.44M | 111.53%603K | -87.62%672K | 403.18%1.24M | 86.09%-75K | -121.81%-749K | -251.45%-5.23M |
| -Change in other current liabilities | -12.82%-44K | -29.41%-44K | 27.78%-26K | -23.97%-150K | -24.24%-41K | -5.41%-39K | -9.68%-34K | -80.00%-36K | ---121K | ---33K |
| -Change in other working capital | -130.14%-336K | 89.94%-131K | -631.82%-117K | -164.02%-1.69M | -197.03%-261K | -201.39%-146K | -528.99%-1.3M | -99.09%22K | 425.95%2.64M | 268.13%269K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -64.65%-6.85M | -62.26%-6M | -167.80%-7.24M | 13.57%-16.02M | 46.43%-5.46M | -103,925.00%-4.16M | 31.01%-3.7M | 9.47%-2.71M | -410.41%-18.53M | -10,183.17%-10.18M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 83.33%-3K | 0 | 14.04%-147K | -200.00%-30K | -152.17%-58K | -350.00%-18K | 69.40%-41K | -533.33%-171K | 62.96%-10K |
| Net PPE purchase and sale | --0 | 83.33%-3K | --0 | 14.04%-147K | -200.00%-30K | -152.17%-58K | -350.00%-18K | 69.40%-41K | -533.33%-171K | 62.96%-10K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 83.33%-3K | --0 | 14.04%-147K | -200.00%-30K | -152.17%-58K | -350.00%-18K | 69.40%-41K | -533.33%-171K | 62.96%-10K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 11,066.67%329K | -106.59%-138K | 120,030.00%11.99M | -18.48%4.52M | -52.57%2.44M | -100.35%-3K | 660.16%2.1M | 89.01%-10K | -89.58%5.55M | -88.91%5.14M |
| Net issuance payments of debt | 13.95%-185K | 13.81%-181K | 14.01%-178K | 41.91%-811K | 12.68%-179K | 46.38%-215K | 46.97%-210K | 47.46%-207K | -420.90%-1.4M | 23.51%-205K |
| Net common stock issuance | 134.43%497K | --0 | 6,131.98%12.28M | 0.15%5.33M | -50.83%2.62M | --212K | --2.31M | --197K | -87.96%5.32M | --5.32M |
| Proceeds from stock option exercised by employees | --17K | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 421.94%1.62M | -91.05%23K |
| Net other financing activities | --0 | ---22K | ---106K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 11,066.67%329K | -106.59%-138K | 120,030.00%11.99M | -18.48%4.52M | -52.57%2.44M | -100.35%-3K | 660.16%2.1M | 89.01%-10K | -89.58%5.55M | -88.91%5.14M |
| Net cash flow | ||||||||||
| Beginning cash position | -23.28%28.53M | -10.66%34.67M | -28.01%29.92M | -24.05%41.56M | -29.27%32.97M | -18.75%37.19M | -24.65%38.81M | -24.05%41.56M | 954.56%54.72M | 460.89%46.61M |
| Current changes in cash | -54.48%-6.52M | -279.12%-6.14M | 272.31%4.75M | 11.51%-11.64M | 39.69%-3.05M | -601.43%-4.22M | 71.77%-1.62M | 14.22%-2.76M | -126.56%-13.16M | -110.88%-5.05M |
| Effect of exchange rate changes | --0 | --0 | --0 | 500.00%4K | --0 | 133.33%1K | 66.67%-1K | 300.00%4K | 90.91%-1K | 116.67%4K |
| End cash Position | -33.24%22.01M | -23.28%28.53M | -10.66%34.67M | -28.01%29.92M | -28.01%29.92M | -29.27%32.97M | -18.75%37.19M | -24.65%38.81M | -24.05%41.56M | -24.05%41.56M |
| Free cash flow | -62.38%-6.85M | -61.55%-6M | -163.80%-7.24M | 13.57%-16.17M | 46.18%-5.49M | -15,525.93%-4.22M | 30.72%-3.71M | 12.04%-2.75M | -411.32%-18.7M | -13,875.68%-10.19M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data